<|begin_of_text|><|begin_of_text|><|begin_of_text|>Plenty of sector and industry exchange traded funds have been adversely affected by presidential election year rhetoric. Biotechnology ETFs have, until recently, been hampered by harsh commentary on drug prices from Democratic nominee Hillary Clinton.
Conversely, it<wm>'s likely to be another election year in tech, with the US-China trade dispute and competitive technologies dominating the agenda.
By the time I started following these areas closely, a massive 34% drop in one major biotech ETF index value occurred between Election Day in January 2016 and September of that year.
For context, the top 100 most traded stocks during the campaign season in January 2016, held steady at the start of the campaign season. Yet biotech, with one major ETF</wm>, fell by approximately $60 billion between January and December of that season.
According to the ETF provider